2,448 results match your criteria Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Five New Things.

Chafic Karam

Neurol Clin Pract 2022 Jun;12(3):258-262

Department of Neurology, University of Pennsylvania, Philadelphia.

Purpose Of Review: The purpose of this review is to give an update on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Recent Findings: There are several recent developments in CIDP, the major one being the 2021 second revision of the European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Other updates address therapy in CIDP, antibodies, serum neurofilament light chain, chronic immune sensory polyradiculopathy (CISP) and CIDP mimics. Read More

View Article and Full-Text PDF

Chronic inflammatory demyelinating polyradiculoneuropathy concomitant with nephropathy.

Neurol Sci 2022 Jun 23. Epub 2022 Jun 23.

Department of Neurology, Peking Union Medical College Hospital, Beijing, 100730, China.

Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is one of the most common autoimmune peripheral neuropathies in adults. Membranous nephropathy (MN), focal segmental glomerulosclerosis (FSGS), and other nephropathy have been reported in CIDP patients and are possibly correlated to CIDP pathogenesis. This study reviewed the previously described cases of patients with CIDP and nephropathy in order to provide comprehensive evidence on the diagnosis and treatment regarding CIDP patients in the context of renal diseases. Read More

View Article and Full-Text PDF

Rituximab in chronic immune mediated neuropathies: a systematic review.

Neuromuscul Disord 2022 May 24. Epub 2022 May 24.

Brain and Nerve Research Centre, Concord Clinical School, University of Sydney, Sydney, Australia. Electronic address:

Chronic immune mediated neuropathy is a heterogenous group of peripheral nerve diseases, encompassing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), autoimmune nodopathy, multifocal motor neuropathy (MMN), and anti-myelin-associated glycoprotein (MAG) neuropathy. Rituximab (RTX) is a chimeric monoclonal antibody targeting the CD20 antigen, which has been used in the treatment of autoimmune neuropathies, although the efficacy of RTX remains unclear. A literature search was performed using Medline, Embase and Cochrane Register for studies between 2000 and 2021 using the search terms "Chronic inflammatory demyelinating polyneuropathy" OR "Multifocal motor neuropathy" OR "Myelin associated glycoprotein" OR "Distal acquired demyelinating neuropathy" OR "Multifocal acquired demyelinating sensory and motor neuropathy" OR "demyelinating neuropathy" AND "Rituximab". Read More

View Article and Full-Text PDF

Spinal canal decompression for hypertrophic neuropathy of the cauda equina with chronic inflammatory demyelinating polyradiculoneuropathy: A case report.

World J Clin Cases 2022 May;10(13):4294-4300

Department of Epilepsy, The Kunming Children's Hospital, Kunming 650100, Yunnan Province, China.

Background: Hypertrophic neuropathy of the cauda equina (HNCE) is a rare disease, especially in children. It can be caused by different etiological agents such as inflammation, tumor or hereditary factors. Currently, there is no uniform standard for clinical treatment of HNCE. Read More

View Article and Full-Text PDF

Usefulness and prognostic value of diagnostic tests in patients with possible chronic inflammatory demyelinating polyradiculoneuropathy.

Muscle Nerve 2022 Jun 4. Epub 2022 Jun 4.

Department of Neurology, University Hospital, Saint-Etienne, France.

Introduction/aims: Recent guidelines define chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and possible CIDP. The aims of our study were to evaluate the value of diagnostic tests to support the diagnosis of CIDP in patients with possible CIDP and to identify prognostic factors of therapeutic success.

Methods: We conducted an observational retrospective two-center study between 2014 and 2019. Read More

View Article and Full-Text PDF

Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.

Pharmaceuticals (Basel) 2022 May 15;15(5). Epub 2022 May 15.

Prince of Wales Clinical School, University of New South Wales, Sydney 2052, Australia.

Peripheral nerve disorders are caused by a range of different aetiologies. The range of causes include metabolic conditions such as diabetes, obesity and chronic kidney disease. Diabetic neuropathy may be associated with severe weakness and the loss of sensation, leading to gangrene and amputation in advanced cases. Read More

View Article and Full-Text PDF

Rituximab Responsive Relapsing-Remitting IgG4 Anticontactin 1 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Associated With Membranous Nephropathy: A Case Description and Brief Review.

J Clin Neuromuscul Dis 2022 Jun;23(4):219-226

Department of Neurology, Centre de Référence Neuromusculaire, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.

Abstract: Nodal/paranodal IgG4-related chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) rarely involves anticontactin (CNTN1) subtype and exceptionally complicates with nephrotic syndrome. A 65-year-old man developed weakness, facial palsy, and balance impairment; after spontaneous recovery, he severely relapsed 1 month later. Electroneuromyography confirmed CIDP. Read More

View Article and Full-Text PDF

High-dose immunoglobulin-dependent chronic demyelinating inflammatory polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis.

eNeurologicalSci 2022 Jun 11;27:100404. Epub 2022 May 11.

Department of Neurology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.

Immunoglobulin G therapy for chronic inflammatory demyelinating polyneuropathy (CIDP) often requires individual dose adjustments because of the heterogeneity of pathogenesis and varying catabolic rates. However, currently available pharmacokinetic studies of immunoglobulin G therapy do not consider individual differences. We conducted a pharmacokinetic study of both intravenous immunoglobulin and subcutaneous immunoglobulin in a single patient with CIDP who was dependent on high-dose immunoglobulin treatment. Read More

View Article and Full-Text PDF

[CIDP Refractory to Three Types of Mainstay Treatments: Differential Diagnosis and Treatment Strategies].

Masahiro Iijima

Brain Nerve 2022 May;74(5):517-524

Department of Advanced Medicine, Nagoya University Graduate School of Medicine.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a syndrome constructed by several clinical phenotypes that share chronic inflammatory demyelination in the peripheral nervous system. While the detailed pathogenesis is not elucidated, mainstay induction therapies such as corticosteroids, IVIg, and plasma exchange, are effective for typical CIDP. However, most conventional treatments show inadequate responses in CIDP variants. Read More

View Article and Full-Text PDF

[CIDP Refractory to Three Types of Mainstay Treatments: Appropriate Induction Therapy and Evaluation of Therapeutic Effect].

Kenichi Kaida

Brain Nerve 2022 May;74(5):510-516

Department of Neurology, Saitama Medical Center, Saitama Medical University.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a disease with a heterogeneous pathology. The responsiveness to mainstay treatment differs depending on the type of CIDP. The treatment strategy is determined based on the type of CIDP, characteristics of the therapeutic agents and treatment methods, and patient background. Read More

View Article and Full-Text PDF

Original Surgical Treatment and Long-term Follow-up for Chronic Inflammatory Demyelinating Polyradiculoneuropathy Causing A Compressive Cervical Myelopathy.

Neurospine 2022 May 17. Epub 2022 May 17.

Vertebra, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic relapsing disease of unknown aetiology. The diagnosis of this disease is still very complicated. The treatment is medical but, in some cases, a surgical decompression might be required. Read More

View Article and Full-Text PDF

Are Miller Fisher syndrome and CANDA due to a paranodopathy?

J Neurol Sci 2022 Jul 10;438:120279. Epub 2022 May 10.

Department of Neurology, Nerve-Muscle Unit, AOC National Reference Center for Neuromuscular Disorders, ALS Center, University Hospital of Bordeaux (CHU Bordeaux - Pellegrin Hospital), Place Amélie Raba-Léon, 33000 Bordeaux, SM, France. Electronic address:

Objective: To study the pathological characteristics of acute and chronic ataxic peripheral neuropathy at the level of the node of Ranvier.

Study Design And Setting: We performed the pathological study (nerve biopsy of a sural nerve) of two patients, one with an acute form of ataxic peripheral neuropathy called 'Miller Fisher syndrome' (MFS), the other one with a chronic form called 'chronic ataxic neuropathies with disialosyl antibodies' (CANDA).

Results: A dysimmune process involving peripheral nerves commences in myelin, at the internodal area or/and in the paranodal and nodal regions. Read More

View Article and Full-Text PDF

Intravenouse immunoglobuline in dysautonomia.

Clin Immunol 2022 Jul 13;240:109039. Epub 2022 May 13.

Federal State Budget Educational Institution of Higher Education "St. Petersburg State University", University Emb., 7-9, Saint-Petersburg 199034, Russia; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, 52621 Tel Ha Shomer, Israel; Ariel University, Ariel, Israel.

Nowadays intravenous immunoglobulin (IVIg) treatment is considered to play a promising role in the autoimmune disease therapy. Despite its significant beneficial effects, the precise mechanism of action needs further studies, as well as recommended dosage in the treatment of autoimmune dysautonomia. In some diseases, like Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating neuropathy (CIDP), IVIg has a strong evidence that allows to recommend and prescribe the medication, while in other diseases only single case studies are available that requires further research. Read More

View Article and Full-Text PDF

Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands.

J Peripher Nerv Syst 2022 May 14. Epub 2022 May 14.

Department of Neurology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare but disabling disorder that often requires long-term immunomodulatory treatment. Background incidence rates and prevalence and risk factors for developing CIDP are still poorly defined. In the current study, we used a longitudinal population-based cohort study in The Netherlands to assess these rates and demographic factors and comorbidity associated with CIDP. Read More

View Article and Full-Text PDF

Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post-hoc analysis of the immunoglobulin overtreatment in CIDP trial.

J Peripher Nerv Syst 2022 Jun 25;27(2):144-158. Epub 2022 May 25.

Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

It is unclear whether frequently used cutoff values for outcome measures defining minimal clinically important differences (MCIDs) can accurately identify meaningful deterioration in chronic inflammatory demyelinating polyneuropathy (CIDP). We used data from the immunoglobulin overtreatment in CIDP (IOC) trial, in which 60 clinically stable patients with CIDP were randomized to intravenous immunoglobulin (IVIg) withdrawal or continuation. We calculated change scores of the Inflammatory Rasch-Built Overall Disability Scale (I-RODS), grip strength, and Medical Research Council-sum score (MRC-SS) and classified visits based on a treatment anchor (ie, decision to restart/increase treatment after reaching a predefined early endpoint of deterioration). Read More

View Article and Full-Text PDF

[What have we learned about chronic inflammatory demyelinating polyradiculoneuropathyin the last twenty years ?]

Rev Med Suisse 2022 Apr;18(779):808-812

Service de neurologie, Département des neurosciences cliniques, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.

chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has been widely described during the last quarter of the twentieth century. The last 20 years have seen decisive progress in its understanding. The diagnostic criteria have been simplified and the steps of the diagnostic process have been clarified. Read More

View Article and Full-Text PDF

Chronic Inflammatory or Chronic Inflammatory Demyelinating Polyradiculoneuropathy?

Front Neurol 2022 4;13:862335. Epub 2022 Apr 4.

Department of Neurology (Nerve-Muscle Unit), AOC National Reference Center for Neuromuscular Disorders, ALS Center, University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, Bordeaux, France.

View Article and Full-Text PDF

Two CIDP Variants Patients With Anti-Caspr1 Antibodies in South China.

Front Immunol 2022 11;13:844036. Epub 2022 Mar 11.

Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Background And Objectives: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is considered an immune-mediated heterogeneous disease that involves both cellular and humoral immunity. The advent of the new concept of node-paranodopathy in recent years has boosted the identification of more antibody-positive CIDP variants patients. Cases of Caspr1 autoantibodies are the least common. Read More

View Article and Full-Text PDF

Prevalence and determinants of pain in chronic inflammatory demyelinating polyneuropathy: Results from the German INHIBIT registry.

Eur J Neurol 2022 Jul 12;29(7):2109-2120. Epub 2022 Apr 12.

Department of Neurology, St. Josef-Hospital - University Hospital, Ruhr-University Bochum, Bochum, Germany.

Background And Purpose: Pain, fatigue and depression in chronic inflammatory demyelinating polyneuropathy (CIDP) are often underestimated, as the focus lies on sensorimotor dysfunction and gait instability. The aim of this study was to investigate their prevalence, characteristics and contribution to disability in a prospective cohort of 84 patients with CIDP.

Methods: Pain, fatigue, depression and quality of life were measured using the Pain Detect Questionnaire, Krupp's Fatigue Severity Scale, Beck Depression Inventory II and the German Short-Form 36 Health Survey. Read More

View Article and Full-Text PDF

[Intravenous immunoglobulin-induced eczematous eruption in autoimmune neuromuscular diseases].

Rinsho Shinkeigaku 2022 Apr 29;62(4):267-271. Epub 2022 Mar 29.

Department of Clinical Neuroscience and Neurology, Yamaguchi University Graduate School of Medicine.

Background: Intravenous immunoglobulin (IVIg) have been administrated for the long time in patients with several autoimmune neuromuscular diseases. Eczematous eruption has been described as IVIg-induced adverse effect.

Objective: The purpose of this study is to clarify the incidence and characteristic of IVIg-induced eczematous eruption in autoimmune neuromuscular disease. Read More

View Article and Full-Text PDF

[65 years old man of chronic inflammatory demyelinating polyneuritis (CIDP) which presented radicular swelling and was able to confirm image progress before the onset].

Rinsho Shinkeigaku 2022 Apr 29;62(4):272-276. Epub 2022 Mar 29.

Department of Neurology, Niigata Prefectural Central Hospital.

The case is a 65 years old man. He noticed muscle weakness of lower limbs from 3 years ago. Dysesthesia was developed, He came in our hospital in X year. Read More

View Article and Full-Text PDF

Nerve ultrasound characteristics of immunoglobulin M neuropathy associated with anti-myelin-associated glycoprotein antibodies.

Muscle Nerve 2022 06 8;65(6):667-675. Epub 2022 Apr 8.

Department of Neurology, Kansai Electric Power Hospital, Osaka, Japan.

Introduction/aims: Immunoglobulin M neuropathy associated with anti-myelin-associated glycoprotein antibody (IgM/anti-MAG) neuropathy typically presents with chronic, distal-dominant symmetrical sensory or sensorimotor deficits. Ultrasonographic studies of IgM/anti-MAG neuropathy are limited, and were all performed on Western populations. We aimed to characterize the nerve ultrasonographic features of IgM/anti-MAG neuropathy in the Japanese population and evaluate whether they differ from the findings of the common subtypes of chronic inflammatory demyelinating polyneuropathy (CIDP). Read More

View Article and Full-Text PDF

Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.

Neurotherapeutics 2022 Mar 28. Epub 2022 Mar 28.

Department of Medicine, Hematology Unit, University of Padova, Padova, Italy.

Autoimmune diseases of the peripheral nervous system have so far been treated mainly with exogenous high-dose intravenous immunoglobulins (IVIg), that act through several mechanisms, including neutralization of pathogenic autoantibodies, modulation of lymphocyte activity, interference with antigen presentation, and interaction with Fc receptors, cytokines, and the complement system. Other therapeutic strategies have recently been developed, in part to address the increasing shortage of IVIg, prime among which is the use of B cell depleting monoclonal antibodies, or small molecule inhibitors targeting the B-cell specific kinases. Rituximab, a chimeric monoclonal antibody against CD20 + B lymphocytes, is currently the most used, especially in anti-MAG antibody neuropathy and autoimmune neuropathies with antibodies to nodal/paranodal antigens that are unresponsive to IVIg. Read More

View Article and Full-Text PDF

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Current Therapies and Future Approaches.

Curr Pharm Des 2022 Mar 25. Epub 2022 Mar 25.

Department of Neurology, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated polyradiculoneuropathy leading to disability via inflammatory demyelination of peripheral nerves. Various therapeutic approaches with different mechanisms of action are established for the treatment of CIDP. Of those, corticosteroids, intravenous or subcutaneous immunoglobulin, or plasma exchange are established first-line therapies as suggested by the recently revised EAN/PNS guidelines for the management of CIDP. Read More

View Article and Full-Text PDF

[Prognostic and monitoring biomarkers in chronic inflammatory demyelinating polyneuropathy].

Rev Neurol 2022 04;74(7):232-241

Hospital Universitari Vall d'Hebron, 08035 Barcelona, España.

Introduction: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a clinical entity with significant phenotypic variability both in its onset and in its course. Therefore, it is important to have objective biomarkers with which to monitor its evolution. In this review we present clinical, neurophysiological, neuroimaging, blood and cerebrospinal fluid (CSF) biomarkers for the monitoring and prognosis of CIDP. Read More

View Article and Full-Text PDF

Diabetes Mellitus Is a Possible Risk Factor for Nodo-paranodopathy With Antiparanodal Autoantibodies.

Neurol Neuroimmunol Neuroinflamm 2022 05 21;9(3). Epub 2022 Mar 21.

From the Department of Neurology (L.A., J.M., K.S., D.H., A.-M.B., H.S., B.F., C.S., K.D.), University Hospital of Würzburg; Department of Neurology (I.A., K.P.), St. Josef Hospital Bochum, Ruhr University of Bochum, Germany; Department of Neurology (I.A.), I.M. Sechenov First Moscow State Medical University, Russia; Department of Neurology (F.B., C.D.), University Medical Center of the Johannes Gutenberg University, Mainz; Department of Neurology (J.D., S.M.), University Hospital Ulm; German Center for Neurodegenerative Diseases (DZNE) (J.D.), Ulm; Department of Neurologic Rehabilitation (F.D.), Asklepios Schloßberg-Klinik, Bad König; Department of Neurology (A.G.), Tübingen University Hospital; Hans Berger Department of Neurology (A.J.), Jena University Hospital; Neuroimmunology Section (F.L.), Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel/Lübeck; Department of Neurology (F.L.), Kiel University; Department of Neurology (M.M.), Klinikum Würzburg Mitte gGmbH, Standort Juliusspital; Department of Neurology (P.M.), LVR-Klinik, Bonn; Department of Pathology (M.R.), Julius Maximilian University of Würzburg; Department of Neurology (A.-D.S.), Sächsisches Krankenhaus Altscherbitz, Schkeuditz; Department of Neurology (M.W.), Bundeswehrkrankenhaus Ulm; and Department of Neurology (G.S.W.), KRH Klinikum Nordstadt, Hannover, Germany.

Background And Objectives: Nodo-paranodopathies are peripheral neuropathies with dysfunction of the node of Ranvier. Affected patients who are seropositive for antibodies against adhesion molecules like contactin-1 and neurofascin show distinct clinical features and a disruption of the paranodal complex. An axoglial dysjunction is also a characteristic finding of diabetic neuropathy. Read More

View Article and Full-Text PDF

Inflammatory demyelinating polyneuropathy after the ChAdOx1 nCoV-19 vaccine may follow a chronic course.

J Neurol Sci 2022 05 16;436:120231. Epub 2022 Mar 16.

Department of Medicine, Launceston General Hospital, 274-280 Charles Street, Launceston TAS 7250, Australia.

Background: Rare autoimmune neurological events have been reported during the ongoing global drive for mass vaccination as a means of controlling the Covid-19 pandemic. Guillain-Barré syndrome, an acute inflammatory neuropathy well recognised as a rare complication of influenza vaccination, has been reported to follow administration of the ChAdOx1 nCoV-19 (AstraZeneca) vaccine.

Methods: We report four patients with inflammatory demyelinating polyneuropathy after vaccination in whom a relapsing or progressive course indicated the development of chronic inflammatory demyelinating polyneuropathy (CIDP). Read More

View Article and Full-Text PDF

Clinical and diagnostic features of anti-neurofascin-155 antibody-positive neuropathy in Han Chinese.

Ann Clin Transl Neurol 2022 05 21;9(5):695-706. Epub 2022 Mar 21.

Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Objective: To investigate the clinical features of Han Chinese patients with anti-neurofascin-155 (NF155) antibody-positive neuropathy.

Methods: We screened 194 patients with peripheral neuropathy for NF155 antibodies using a cell-based assay (CBA) and teased-fiber immunofluorescence assay. We summarized the clinical findings of seropositive patients. Read More

View Article and Full-Text PDF

Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.

J Peripher Nerv Syst 2022 Jun 15;27(2):159-165. Epub 2022 Mar 15.

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Clinical trials in chronic inflammatory demyelinating polyneuropathy (CIDP) often assess efficacy using the ordinal Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. Here, data from the PATH study was reanalyzed using change in Inflammatory Rasch-built Overall Disability Scale (I-RODS) to define CIDP relapse instead of INCAT. The PATH study comprised an intravenous immunoglobulin (IVIG) dependency period and an IVIG (IgPro10 [Privigen]) restabilization period; subjects were then randomized to weekly maintenance subcutaneous immunoglobulin (SCIG; IgPro20 [Hizentra]) 0. Read More

View Article and Full-Text PDF

Nerve Ultrasound Performances in Differentiating POEMS Syndrome from CIDP.

Neurotherapeutics 2022 Mar 7;19(2):455-463. Epub 2022 Mar 7.

Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Chronic inflammatory demyelinating polyneuropathy (CIDP) and polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome are both acquired demyelinating polyneuropathies. We aim to explore the different features of ultrasonographic changes between CIDP and POEMS syndrome. Nerve ultrasonographic studies were performed in 120 patients with CIDP and 34 patients with POEMS syndrome. Read More

View Article and Full-Text PDF